Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (7)

Showing 1-7 of 7

Sorted By:

A-Z
Z-A

Previous Next

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases (ECLIPSE)
compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy according to physician's choice (control arm) in HNSCC.
A092205_HNSCC: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
PhIII Trial of Pembro vs Pembro/Cetux in Recurrent or Metastatic HN Squamous Cell Carcinoma with Platinum Refractory Disease
BI_1463-0001: An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC)
Ph I of BI 765179 as monotherapy and combo with ezabenlimab (BI 754091) in patients with solid cancers, BI 765179 in combo with pembro in first-line PD-L1-positive(HNSCC)
D798EC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
main purpose is to assess efficacy and safety of volrustomig compared to observation in participants with LA-HNSCC who have not progressed after cCRT
EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
NRG-HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-stage Oral Cavity Cancer
how well sentinel lymph node biopsy works & compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer

Previous Next